ZFHX4 mutation as a novel predictive biomarker for immune checkpoint blockade in non-small cell lung cancer.

被引：0
|
作者：
Shen, Peng
Zeng, Di
Lin, Zhenzi
Lin, Pei
Luo, Mingyang
Zhao, Lele
Chai, Huizi
Huang, Lingli
Xiao, Mingzhe
机构：
[1] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[2] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[3] Jiangsu Sim cere Diagnost Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Jiangsu Simcere Diagnost Co, Nanjing, Peoples R China
[4] Jiangsu Simcere Diagnost Co Ltd, Dept Med, Nanjing, Peoples R China
[5] Jiangsu Simcere Diagnost Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20535
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma
    Fu, Cong
    Gu, Haoran
    Sun, Lin
    Wang, Zhouyu
    Zhang, Qin
    Luo, Ningning
    Chen, Dongsheng
    Zhou, Tong
    INVESTIGATIONAL NEW DRUGS, 2024, : 623 - 634
  • [2] ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
    Jiexia Zhang
    Ningning Zhou
    Anqi Lin
    Peng Luo
    Xin Chen
    Huojin Deng
    Shijun Kang
    Linlang Guo
    Weiliang Zhu
    Jian Zhang
    Cancer Immunology, Immunotherapy, 2021, 70 : 137 - 151
  • [3] ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
    Zhang, Jiexia
    Zhou, Ningning
    Lin, Anqi
    Luo, Peng
    Chen, Xin
    Deng, Huojin
    Kang, Shijun
    Guo, Linlang
    Zhu, Weiliang
    Zhang, Jian
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (01) : 137 - 151
  • [4] PTPRD: A Positive Predictive Biomarker for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
    Shen, J.
    Zhou, H.
    Liu, J.
    Zhang, Y.
    Zhou, T.
    Hong, S.
    Zhao, Y.
    Yang, Y.
    Zhao, H.
    Huang, Y.
    Fang, W.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S335 - S336
  • [5] WDR49 mutation as a novel predictive biomarker in patients with non-small cell lung cancer with immune checkpoint inhibitors
    Shi, Zhihui
    Liu, Yaqin
    Zhao, Lele
    Chen, Lin
    Yang, Qidong
    Xiao, Mingzhe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
    Sun, Lei
    Li, Man
    Deng, Ling
    Niu, Yuchun
    Tang, Yichun
    Wang, Yu
    Guo, Linlang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [7] The effect of tumor mutation burden on immune checkpoint inhibitors in non-small cell lung cancer.
    Zhao, Jie
    Dong, Yiting
    Bai, Hua
    Duan, Jianchun
    Wang, Guoqiang
    Xu, Jiachen
    Wang, Zhijie
    Wang, Jie
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Cui, Yanan
    Liu, Xinyin
    Wu, Yuemin
    Liang, Xiao
    Dai, Jiali
    Zhang, Zhihong
    Guo, Renhua
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.
    Park, Sehhoon
    Ahn, Chang Ho
    Jung, Geunyoung
    Lee, Sarah
    Paeng, Kyunghyun
    Shin, Jiwon
    Yoo, Inwan
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    La Choi, Yoon
    Song, Sang-Yong
    Lee, Se-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Role of the THE in immune checkpoint blockade resistance of non-small cell lung cancer
    Dai, Yuening
    Tian, Xueqi
    Ye, Xuanting
    Gong, Yabin
    Xu, Ling
    Jiao, Lijing
    CANCER DRUG RESISTANCE, 2024, 7
12345